ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway

Zhang, Li-ying; Yu, Jia-ying; Leng, Yan-long; Zhu, Ran-ran; Liu, Hong-xian; Wang, Xin-yu; Yang, Ting-ting; Guo, Yi-ning; Tang, Jing-ling*; Zhang, Xin-chen*哈尔滨医科大学
Cancer Gene Therapy2022-6DOI: 10.1038/s41417-021-00356-y
5被引7阅读
引用收藏
分享

摘要

Primary cytoreductive surgery with platinum-taxane-based chemotherapy is the standard treatment for ovarian cancer (OC) patients; however, resistance to chemotherapy is a contributing factor to OC mortality. Paclitaxel (PTX), the most widely used taxane, has become the first-line drug against OC. The molecular mechanism of PTX resistance is different from that of platinum-based agents and is still not completely elucidated. Our previous study showed that glucose-regulated protein 78 (GRP78) is involved in the resistance of OC cells to PTX. However, little is known regarding endogenous inhibitors of this gene. MicroRNAs (miRNAs) play critical roles in the regulation of gene expression; therefore, we sought to identify miRNA(s) with potential to target GRP78 under the hypothesis that miRNA(s) could serve as potential therapeutic targets. Here, we show that miR-181c, predicted to target GRP78, was downregulated in PTX-resistant OC cells and tissues. MiR-181c downregulated GRP78 expression and induced apoptosis by directly targeting its 3 '-untranslated region (UTR). Overexpression of miR-181c sensitized resistant OC to PTX by inhibiting the PI3K/Akt pathway in vitro and in vivo. Taken together, our findings indicate that the delivery of miR-181c can efficiently suppress GRP78 expression and GRP78-mediated PTX resistance in OC and suggest that this strategy has therapeutic potential.

学科与关键词

关键词
MULTIDRUG-RESISTANCECISPLATIN RESISTANCEDOWN-REGULATIONPROTEIN GRP78UP-REGULATIONPROLIFERATIONINHIBITIONMECHANISMCHEMOSENSITIVITYCHEMORESISTANCE
相关
加载中…
  • MiR-4284 inhibits sensitivity to paclitaxel in human ovarian carcinoma SKOV3ip1 and HeyA8 cells by targeting DMC1
    Sun, Dongyan*; Shang, Di; Miao, Pan; Jiang, Zhihe; Chen, Yanling; Gao, JianAnti-Cancer Drugs, 2022, 33(8): 701-709.被引 2
  • CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression
    Huang, Chunyan; Qin, Li; Chen, Sailan; Huang, Qin*Anti-Cancer Drugs, 2023, 34(3): 395-404.被引 2
  • Radix ranunculus temate saponins sensitizes ovarian cancer to Taxol via upregulation of miR-let-7b
    You, Keli; Liu, Yuejun; Chen, Le; Ye, Haiyan*; Lin, Wumei*Experimental and Therapeutic Medicine, 2022, 23(5): 315.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Gene Therapy
发表日期
2022-06
卷期
第 29 卷, 第 6 期
页码
770-783
DOI
10.1038/s41417-021-00356-y
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81602273]

作者

  • Z

    Zhang, Li-ying (第一作者)

    2 · harbin med univ

  • Y

    Yu, Jia-ying

    2 · harbin med univ

查看全部 10 位作者收起作者
  • L

    Leng, Yan-long

    2 · harbin med univ

  • Z

    Zhu, Ran-ran

    2 · harbin med univ

  • L

    Liu, Hong-xian

    2 · harbin med univ

  • W

    Wang, Xin-yu

    2 · harbin med univ

  • Y

    Yang, Ting-ting

    2 · harbin med univ

  • G

    Guo, Yi-ning

    2 · harbin med univ

  • T

    Tang, Jing-ling (通讯)

    harbin med univ

  • Z

    Zhang, Xin-chen (通讯)

    2 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417